AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

17, 2025 (GLOBE NEWSWIRE) -- HER2+ Non-Small Cell Lung Cancer Market is Predicted ... the highest revenue was generated by Checkpoint inhibitors ± Chemotherapy, i.e., USD ~480 million in the ...

BAY 2927088 is an oral small-molecule tyrosine kinase inhibitor designed to selectively target mutant HER2, including HER2 exon 20 insertions and point mutations, as well as EGFR while maintaining ...

New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight The treatment ...

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

ATX968 was identified as a potent and selective inhibitor of DHX9 helicase activity ... For SMARCA2 ATPase assay, custom plasmid DNA was prepared by Viva Biosciences. ATPase assays were performed in ...